Last C$10.28 CAD
Change Today +0.27 / 2.70%
Volume 123.0K
TKM On Other Exchanges
As of 3:59 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

tekmira pharmaceuticals corp (TKM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - C$34.66
52 Week Low
07/25/13 - C$4.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

tekmira pharmaceuticals corp (TKM) Related Bloomberg News

View More Bloomberg News

tekmira pharmaceuticals corp (TKM) Related Businessweek News

No Related Businessweek News Found

tekmira pharmaceuticals corp (TKM) Details

Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Its pipeline products include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials, which targets polo-like kinase 1, a protein involved in tumor cell proliferation and a validated oncology target; and TKM-HBV, which is in Phase I clinical trial to eliminate surface antigen expression in the chronically infected patients. The company is also involved in developing TKM-Ebola, an anti-ebola viral therapeutic that is in Phase I clinical trial; and TKM-Marburg to treat Marburg infections. In addition, its preclinical product candidate includes TKM-ALDH2 for the treatment of alcohol use disorder. The company has strategic alliances with Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Monsanto Company; Marina Biotech, Inc./Arcturus Therapeutics, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and U.S. National Institutes of Health. Tekmira Pharmaceuticals Corporation is headquartered in Burnaby, Canada.

tekmira pharmaceuticals corp (TKM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $377.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $69.5K
Chief Technical Officer and Executive Vice Pr...
Total Annual Compensation: $305.9K
Senior Vice President of Pharmaceutical Devel...
Total Annual Compensation: $233.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $128.6K
Compensation as of Fiscal Year 2013.

tekmira pharmaceuticals corp (TKM) Key Developments

Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold

Tekmira Pharmaceuticals Corporation announced an update on the TKM-Ebola Phase I clinical hold. The company has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) and is preparing a Complete Response to the Agency. The company anticipates this matter will be resolved by fourth quarter of, 2014. Tekmira's other clinical development programs are unaffected by the TKM-Ebola clinical hold and all remain on track. The key milestones for these programs in the second half of 2014 are: presentation of TKM-HBV Pre-Clinical data, filing IND (or equivalent) for TKM-HBV, interim Phase IIa TKM-PLK1 data and nomination of the next product development candidate. The clinical hold letter confirms that the FDA is seeking data to elucidate the mechanism of potential cytokine release and a modification to the protocol for the multiple ascending dose portion of the trial to ensure the safety of healthy volunteers.

Tekmira Receives Notice of Clinical Hold for TKM-Ebola Phase I Clinical Trial

Tekmira Pharmaceuticals Corporation received verbal notice from the U. S. Food and Drug Administration (FDA) that the TKM-Ebola Phase I healthy volunteer clinical study has been placed on clinical hold. This notice applies only to this study.

Tekmira Pharmaceuticals Corporation Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 02:00 PM

Tekmira Pharmaceuticals Corporation Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 02:00 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKM:CN C$10.28 CAD +0.27

TKM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.11 AUD -0.04
Galena Biopharma Inc $2.79 USD +0.08
Marina Biotech Inc $0.51 USD +0.005
Regulus Therapeutics Inc $6.67 USD -0.10
Silence Therapeutics PLC 221.00 GBp 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TKM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.4x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEKMIRA PHARMACEUTICALS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at